Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025

 Toronto, Ontario – TheNewswire - 15 December, 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces the filing of the Company’s unaudited interim financial statements as of and for the three month period ended October 31, 2025 (the “Financial Statements”), the management’s discussion and analysis (“MD&A”), and the certifications of the Ch ...